chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Pt recvd 1st dose of Hep B vax 28MAR91 & on 29MAR91 devel generalized rash; pt noted that had been lying in the sun; ER MD suggested that pt receive no further vax; pt recovered;
Chills  Tremulous  Body aches  Joint pain  Sort throat  Cough  Congestion
basal ganglionic hemorrhagic stroke; basal ganglionic hemorrhagic stroke; This is a spontaneous report from a contactable consumer. This 74-years-old male consumer (Patient) reported for himself that he received first dose of bnt162b2 (BNT162B2) (Batch/Lot Number: EN9581), via an unspecified route of administration in Arm Right on 03Feb2021 at single dose for covid-19 immunization.  Medical history included asthma, atrial fibrillation (A-fib), hypertension (HTN), ischaemic stroke (Ischemic CVA). Concomitant medications included amlodipine; atorvastatin; doxazosin; apixaban (ELIQUIS); lisinopril (LISNOP). No other vaccine in four weeks. The patient experienced basal ganglionic hemorrhagic stroke (hospitalization, disability, life threatening) on 05Feb2021 08:00 with outcome of not recovered. The patient was hospitalized for basal ganglionic hemorrhagic stroke from 05Feb2021 to 21Feb2021. Clinical course reported as follow: Early in the morning hours of 05Feb2021, patient had a basal ganglionic hemorrhagic stroke. He was found 10+ hours later and airlifted from local emergency room to neuro ICU unit. He spent 16 days in hospital then was d/c home for hospice care. Treatment for event included factor ii (prothrombin);factor ix;factor vii (proconvertin);factor x (stuart prower factor);protein c (coagulation inhibitor);protein s (KCENTRA). No covid prior vaccination. No covid tested post vaccination.
Experienced general soreness and redness later that day after receiving vaccine. A little less than 24 hours after receiving vaccination (Prevnar 13), patient experienced extreme pain in arm and was unable to move arm. Felt pain and tenderness in the area. Pain lasted for about 3 days, decreasing in quality every day until the 4th day where patient felt better.
Information has been received from a healthcare worker (immunization official) referring to a 4 year old patient. The patient's medical history, concurrent condition and concomitant therapy were not reported. On 29-JUL-2015, the patient was vaccinated with a dose of (Oka/Merck) VARIVAX, lot # K010440(expiration date, dose and route not reported), which was improperly stored. No adverse effects were reported. This is one of several reports received from the same source. Additional information has been requested.
flushed face; syncope; chills; profuse sweating; dizziness; vomiting; diarrhea; nausea; fatigue; don't know if elevated temperature, but possible; booster; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 62 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in arm right, administration date 03Dec2021 10:30 (Lot number: FJ8757) at the age of 62 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "sulfa allergy" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (lot number EL3247, administrator route Intramuscular, administration time 12:00 PM , dose 2, vaccine location Left Arm), administration date: 13Apr2021, when the patient was 62 years old, for COVID-19 immunization; Bnt162b2 (lot number EL3247, administrator route Intramuscular, administration time 12:00 PM , dose 1, vaccine location Left arm), administration date: 25Mar2021, when the patient was 62 years old, for COVID-19 immunization; Flu vaccine VII (dose 1, vaccine location Left Arm), administration date: 04Nov2021, when the patient was 62 years old, for immunization. The following information was reported: IMMUNISATION (medically significant) with onset 03Dec2021 10:30, outcome "unknown", described as "booster"; SYNCOPE (medically significant) with onset 03Dec2021 20:00, outcome "recovering", described as "syncope"; CHILLS (non-serious) with onset 03Dec2021 20:00, outcome "recovering", described as "chills"; HYPERHIDROSIS (non-serious) with onset 03Dec2021 20:00, outcome "recovering", described as "profuse sweating"; DIZZINESS (non-serious) with onset 03Dec2021 20:00, outcome "recovering", described as "dizziness"; VOMITING (non-serious) with onset 03Dec2021 20:00, outcome "recovering", described as "vomiting"; DIARRHOEA (non-serious) with onset 03Dec2021 20:00, outcome "recovering", described as "diarrhea"; NAUSEA (non-serious) with onset 03Dec2021 20:00, outcome "recovering", described as "nausea"; FATIGUE (non-serious) with onset 03Dec2021 20:00, outcome "recovering", described as "fatigue"; BODY TEMPERATURE INCREASED (non-serious) with onset 03Dec2021 20:00, outcome "recovering", described as "don't know if elevated temperature, but possible", based on chills and sweating; FLUSHING (non-serious) with onset 06Dec2021 (on day 3 after shot), outcome "recovering", described as "flushed face". Therapeutic measures were not taken as a result of syncope, chills, hyperhidrosis, dizziness, vomiting, diarrhoea, nausea, fatigue, body temperature increased, flushing.  No follow-up attempts are possible. No further information is expected.
Information was received from a physician concerning a 13 year old male patient. On an unknown date, the patient was vaccinated with his first dose of GARDASIL. The physician reported that the patient developed a yeast infection underneath an unspecified arm after his first dose of GARDASIL. No further information was provided. Additional information has been requested.
Red, blotchy skin and itchiness st injection site.  Seems to occur primarily in the evenings. It's been 11 days since the injection and symptoms are still persisting.
Per pt Dad through telephone conversation, immunizations given 03/28/05, on 03/30/05 @ 5:00 PM, the right leg was swollen, hard, red,and warm to touch- area size of 50 cent piece- Instructed to give Benadryl 1 tsp Q 6 H x 24 hours cool compress to leg, NO ice. Call back if pain worse.
Has anxiety; This is a spontaneous report from a contactable consumer (patient) via a Pfizer-sponsored program. A female patient of an unspecified age received the 1st dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Batch/Lot number was not reported) via an unspecified route of administration, on Feb2021 (reported as about 3 weeks ago) as single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. On unspecified date in 2021, it was reported that the patient had anxiety about getting the second dose after getting the first dose about 3 weeks ago. The patient wanted to know if she can take lorazepam (ATIVAN). The outcome of the event was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Patient reported that approximately 2 days after vaccination she developed a rash that originated at the injection site and had a generalized spread over her upper body.  No itching, hives, or other issues beyond the rash.
rash to left side of neck/ rash to right side of neck/ Rash to stomach/ Broke out on her face; Hives; Itching; rash, hives and itching that got worst; This is a spontaneous report from a contactable consumer. A 67-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, solution for injection, Lot Number: EK9231, Expire Date: Unknown), via an unspecified route of administration, administered in Arm Left on 19Jan2021 at 11:30 (at the age of 67-year-old) UNKNOWN, SINGLE for covid-19 immunization. Medical history included allergic to penicillin since she was a child with ongoing. The patient's Family Medical History, previous immunization with the Pfizer vaccines, Concomitant medications, Prior vaccination within 4 weeks and additional vaccines administered on same date of the Pfizer suspect reported as none. After receiving the vaccine, the patient waited for 15 minutes but there was no reaction. On 24Jan2021 17:00, on the fifth day after the vaccine, the patient experienced rash to left side of neck, hives and itching that got worst. On 25Jan2021 at 08:00, rash to right side of neck, on 26Jan2021 at 08:00, broke out on her face; on 28Jan2021 at 22:00, rash to stomach appeared. On an unknown date the patient had "rash, hives and itching that got worst". The patient was told that it was a reaction to the vaccine. The patient also stated that she broke out on her face on 28Jan2021 (the day of report). The patient had visit on Physician Office. The patient had to have a steroid shot, prednisone and Benadryl. The patient's hives resolved completely after the steroid shot. The outcome of event rash not recovered. The outcome of the event urticaria was reported as recovered on 27Jan2021. The outcome of the event pruritus was reported as recovering. The outcome of the event condition aggravated was unknown.  No further information expected. Follow up attempts are completed.
Swollen and red lymph node on left side between chest and armpit; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration in the left arm on 10Mar2021 at 14:00 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history included rosacea and allergy to rats. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to COVID vaccine. Concomitant medications included doxycycline (MANUFACTURER UNKNOWN), estradiol (CLIMARA), vitamin d nos (MANUFACTURER UNKNOWN) and fish oil (MANUFACTURER UNKNOWN); all for an unknown indication from an unknown date and unknown if ongoing. On 12Mar2021, the patient experienced swollen and red lymph node on left side between chest and armpit. The events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event swollen and red lymph node on left side between chest and armpit was recovering at the time of the report.   No follow-up attempts are needed. No further information is expected.
lump in throat started 10-20 minutes after vaccine injection on 1/6/2021 and lasted 5-6 hours; called his PCP and referred to allergist ; saw allergist on 2/10/2021 - no treatment  Narrative:  Other Relevant History:
This spontaneous report was received from a healthcare worker regarding an unspecified number of patients of unknown age and gender. There was no information on pertinent medical history and drug reactions or allergies. The reporter reported that on an unknown date an unspecified number of patients were vaccinated with VARIVAX (Merck) (dose, frequency, dose number, product lot#, expiry date, route not reported) that was improperly stored. No adverse effects reported. There was no product quality complaint involved. The outcome of the events was unknown. Additional information has been requested.
she was bending down and had a heavy nose bleed from one nostril; lips and mouth were dry; lips and mouth were dry; This is a spontaneous report from a contactable consumer or other non hcp (patient). A 83-years-old female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID -19 VACCINE, Solution for injection, Lot Number and Expiration date was not reported) via an unspecified route of administration on 03Mar2021 as dose 1, single for COVID-19 immunization. Medical history included ongoing epistaxis. The patient concomitant medications were not reported. It was reported that the day that she received her first vaccine on 03Mar2021, she was bending down and had a heavy nosebleed from one nostril. She had nose bleeds in the past but was not sure if this one might have been triggered from the vaccine. She also mentioned that her lips and mouth were dry. The outcome of the events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot been obtained.
rash onset 7/4/99 arms, torso, neck, back of head;itching;worse @ noc;rash is flat not raised @ all, extremely red;tick bite 3wk ago w/bulls eyes @ that time;to ER 7/5/99;rx cortisone, atarax & unk med;
The week prior, I work in an office of 20 people and I was #12 of being positive for COVID. I woke up, felt funny, had a cough and I went and tested and I was positive for COVID. Saturday through Monday I just did not feel well, then Tuesday I had a fever, chills, body aches and by Monday the following week I still had a fever and cough by Wednesday I felt better.
Headache, pain, sour throat, hot, chills, misery for 2 days.  Now, 2 weeks later still have a persistent cough. Dry, constant.
Had Chest pain 7/19/2021 went to er and was diagnosed with pulmonary embolism. Started on rivaroxaban/ xarelto. Was discharged from ER same day. Stable. Would not say she is "recovered" as we are early out from PE. Stopped combination oral contraception.
Patient is a 77 y.o. female patient of, MD with history of CAD, hyperlipidemia, hypothyroidism, lumbar disease who presented to Hospital with cough, found to have COVID and respiratory failure.   Acute hypoxic respiratory failure COVID-19 Virus Infection Date of onset of symptoms: 3/25/2023 Symptoms present on admission: Myalgias, congestion, cough, shortness of breath Date of covid positive test: 3/25 on home test and confirmed on admission 3/28 Vaccination status: vaccinated with updated bivalent booster Imaging: CXR unremarkable.  CTPA without PE, showed mild lower lobe bilateral opacities Oxygen requirements on admission: 2 L NC Current oxygen requirements: room air Medical therapy: treated with remdesivir and steroids while admitted, given improvement and on room air, will discharge on short course of steroids CRP 113, procal normal Consultants following: none Anticipated special isolation end date: 10 days from symptom onset   CAD Hyperlipidemia Per history, home regimen of pravastatin, aspirin CT chest shows severe coronary artery calcifications  No cardiac symptoms Continue home regimen with outpatient follow up for potential stress test   Hypothyroidism Continue home Synthroid   GERD Continue home PPI
This case was reported by a healthcare professional and described the occurrence of lesion on right lower eyelid and upper lip in a 4-year-old male subject who was vaccinated with KINRIX (GlaxoSmithKline), (non-gsk) PREVNAR. The subject's medical history included febrile seizure. The subject had not experienced adverse events following previous vaccinations. There were no concurrent medications. On 19 October 2010 at 10:30 the subject received 1st dose of KINRIX (.5 ml, unknown, left thigh). On 19 October 2010 the subject received 4th dose of PREVNAR (unknown). On 19 October 2010 at 11:30, 1 hour after vaccination with KINRIX and PREVNAR, the subject experienced lesion on right lower eyelid and upper lip, itching, swelling of tongue and scratchy itchy throat. The subject required medical attention at the doctor's office. The healthcare professional considered the events were clinically significant (or requiring intervention). The subject was treated with BENADRYL and his symptoms resolved. On 19 October 2010, the events were resolved. The healthcare professional considered the events were probably related to vaccination with KINRIX and PREVNAR.
Patient is a 76-year-old male with past medical history significant for diabetes and hypertension who presents to the ED today via EMS complaining of syncopal episode. The patient apparently had received a tetanus booster shot on Tuesday morning and then went to workout at the YMCA. The next day while he was working out he began to notice he was breaking out in hives all over his arms and back. The patient returned to his PCP's office and while he walking in the door he became extremely weak and dizzy and began to pass out. The receptionist helped him to the floor without trauma. The patient was found to be extremely hypotensive at 50/30, questionable loss of pulses and apnea during this event. The patient was given 0.3 mg of subcutaneous epi and EMS was called. The patient immediate woke up from the episode. No seizure activity was noted. No incontinence. No postictal state was described. The patient denies any chest pain, shortness of breath. No nausea, vomiting, diarrhea. No fevers, chills or rigors. Negative exposure to known allergens. On exam, diffuse urticaria was present on the torso, arms, and legs.  Patient improved after admission and had a second episode of diffuse urticaria his first morning in the hospital after eating a breakfast of eggs, bacon, and oatmeal. Patient was monitored in the hospital and given Prednisone 60 mg with a 12 day taper upon discharge.  MR received revealing a 76 yr. old who developed urticaria 1 day following his Td vax.  He presented at the MD's office where he had a 60 second syncopal episode.  HPI: BP was noted to be 50/30 at the time of the syncopal incident and he was taken to the ER via EMS. Questionable loss of pulse and apnea at the time.  Pt was given 0.3 mg of subcutaneous epinephrine prior to transport. Patient was admitted for observation, and had one pre-syncopal event upon admission.  Patient was treated with IV Solumedrol which improved symptoms. Discharged home after 48 hours on a prednisone taper. D/C DX: Syncopal episode and urticaria 2' to allergic reaction to Tetanus booster.
Patient was given second dose of covid vaccine 7 days too early. Patient received first dose on 02/27/2023 and second dose was given on 03/20/2023 when it should have been given on 03/27/2023 at the earliest.
vaccine was administered in error, tried to contact patient to let him know and come back to get the right vaccine.
BABY WAS IN PAIN AND FUSSY. THE FOLLOWING MORNING SHE EXHIBITED TOTAL AUTISM. SHE WOULD NOT SMILE. LOOK INTO YOUR FACE, OR MAKE ANY SOUNDS EXCEPT FOR CRYING AND WHIMPERING.  HER APPETITE DROPPED FROM 22 OUNCES OF FORMULA DAILY TO 16 OUNCES. SHE HAS NOT REGAINED HER APPETITE.  SHE WAS SIMPLY NOT REACTING TO HER ENVIRONMENT AT ALL. THIS WENT ON FOR TWO DAYS, ALL DAY FRIDAY AND SATURDAY, AND ON SUNDAY MORNING, SHE STARTED ACTING NORMAL AGAIN, EXCEPT FOR THE LACK OF APPETITE. A FEW DAYS LATER, WE REPORTED TO THE DOCTOR, WHO SAID WE WOULD POSTPONE OR CANCEL FUTURE DTaP VACCINATIONS.
No additional AE reported; patient received an expired dose of VARIVAX; This spontaneous report as received from a nurse refers to a patient of unknown age and gender.      The patient's concurrent conditions, medical history, and concomitant medications were not reported.   On 01-OCT-2021, the patient was vaccinated with an expired dose of varicella virus vaccine live (oka/merck) (VARIVAX) (lot # S017226, expiration date 04-JUN-2021) at a dose of 0.5 milliliter (dose number, route of administration, and anatomical location were not reported) for prophylaxis.         The reporter confirmed that there were no prior temperature excursions and no additional adverse events (AE) reported.
Pt received MMR and DTaP 5/3/05, mom called office at 3:55 05/04/05 states patient leg reddened, swollen, and warm to touch. Mom states leg became swollen and reddened 05/03/05 PM mom administered at home clinical date 12x9 cm reddened area with induration noted.
Immediately after vaccination #1 at 0945 pt. noted "fuzziness, then cold at injection site and throughout body."  BP at 1010 was 140/100.  By 1040 BP was 130/88 and "coldness" had resolved and "fuzziness" had improved.  States also that her distance vision had been blurred at 0945 but had resolved by 1040.  She left the POD ambulatory at 1050.  Follow up call 3/19 finds no sequelae; pt. reports complete recovery.  Is scheduled for #2 dose 3/31.  Advised to report event and BP spike to her doctor and be advised about receiving 2nd dose.
This spontaneous case was reported by a patient and describes the occurrence of ARTHRITIS (bad arthritis flare up in her leg) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Mar-2021, the patient experienced ARTHRITIS (bad arthritis flare up in her leg). At the time of the report, ARTHRITIS (bad arthritis flare up in her leg) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications reported. No treatment reported
Used wrong diluent on HIB vaccine. Used MMR diluent instead of Hib Diluent.
The employee reported on 10-14-2011 a gradual onset of fever, chills and fatigue that evening. Within 72 hours the employee complained of angioedema to face & eyes and throat discomfort. Hives to torso, back, upper and lower extremities with pain. Today reports pain with eye movement. Reported to Emerg. Room. Treated with DECADRON 10mg & Toradol 130mg IVP.
Redness and swelling over anterior RT and LT thigh. 0.5 cm wheal appeared near injection sight on RT thigh along with a 2cm sized welt under skin. Doctor was notified and assessed the patient. Ice packs applied to both thighs and patient monitored. Swelling and redness decreased and wheal resolved. Welt still palpable but had decreased in size. Patient given Motrin for inflammation and instructed on follow-up care. Attempted to contact parent next morning to check on patient status. Left message to call office back for update
Information has been received from a nurse concerning the granddaughter, a 15 month old female, of a middle aged woman who was vaccinated with varicella virus vaccine live (Oka/Merck) and then developed shingles. Additional information has been requested.
This spontaneous report was received from a physician and refers to a patient of unknown age and gender. No information about the patient's relevant medical history, drug history and concomitant medications was provided. On an unknown date, the patient was vaccinated with a dose of GARDASIL 9 lot # reported as 36301, expiration date December 2017 (dose and route of administration were not provided) that underwent a temperature excursion and had been exposed to a temperature of 32.1 Fahrenheit degrees for 7 hours. The patient did not experience any adverse events. It was unknown if any relevant tests were done. Lot number 36301 is an invalid lot number for GARDASIL 9. This is one of several reports received from the same reporter. Additional information has been requested.
Reaction to immunizations. Lt. lateral mid thigh redden and warm to touch. Treated with KEFLEX, BENADRYL and Ibuprofen.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 66-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 08Jun2022 at 13:30 as dose 4 (booster), single (Lot number: FK9893) at the age of 66 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Osteoporosis" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: Treatment of COVID-19. Therapeutic measures were taken as a result of drug ineffective, covid-19. No Other medication in 2 weeks. No If treatment ae, No Known Allergies